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The present study investigates the encapsulated propolis on blood glycemic control, lipid metabolism, and insulin resistance in
type 2 diabetes mellitus (T2DM) rats. The animal characteristics and biological assays of body weight, fasting blood glucose
(FBG), fasting serum insulin (FINS), insulin act index (IAI), triglycerides (TG), total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured and euglycemic hyperinsulinemic glucose
clamp technique were used to determine these eﬀects. Our ﬁndings show that oral administration of encapsulated propolis can
signiﬁcantlyinhibittheincreasingofFBG andTG inT2DM ratsandcanimproveIAI andM valuein euglycemichyperinsulinemic
clamp experiment. There was no signiﬁcant eﬀects on body weight, TC, HDL-C, and LDL-C in T2DM rats treated with
encapsulated propolis. In conclusion, the results indicate that encapsulated propolis can control blood glucose, modulate lipid
metabolism, and improve the insulin sensitivity in T2DM rats.
1.Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disease
characterized by an elevated blood glucose concentration
that results from inadequate insulin action in insulin-
sensitive tissues and from abnormal insulin secretion. The
number of people diagnosed with T2DM is increasing at an
alarming rate. In the USA, Europe, and most westernized
countries, T2DM aﬀects ∼6% of the population [1]. In big
cities of China, the attack rate also reaches 6% [2]. Ac-
cording to a widely accepted estimation, the number of dia-
betic patients (most of them with T2DM) can reach 366
million by the year 2030, promoted by a dramatic increase
in the incidence of obesity and a sedentary lifestyle [3].
T2DM,especially itsdevelopingcomplications,carries avery
poor prognosis and may lead to a dramatic decrease of life
expectancy. Economical analyses of late complications made
it clear the total cost of care of patients with T2DM and its
complications is very high. Thus, much interest has been
focused on the development of alternative medicinal foods,
which includes screening of natural bioactive compounds
with the ability to improve glucosecontrol and lowerthe risk
of complications [4, 5].
Propolisisasafenaturalproductswhichisaresinoushive
material collected by honeybees from various plant sources.
It is a popular folk medicine possessing a broad spectrum of
biological activities, such as anticancer, antioxidant, antiin-
ﬂammatory, antibiotic, antifungal, and antihepatotoxic [6–
10]. In recent years, there have been many surveys carried
out that propolis has hypoglycemic activity [11–13]a n dh a s
some positive eﬀects on diabetic complications [14, 15].
Researchers explored the way of propolis resist oxidative
damage [16], enhance body immunity, and inﬂuence the
metabolic enzyme to reveal its therapeutic eﬀects on dia-
betes mellitus [17]. However, the eﬀects of propolis on
glycometabolism, lipid metabolism, and insulin resistance in
T2DM rats are uncertain.
Our previous studies showed that propolis ethanol and
water extracts exert a positive eﬀect in diabetic animals [18–
20]. However, as propolis is a strongly adhesive, resinous
mixture ofinsolubleor slightly solublesubstances with bitter
taste, the applicationofpropolisasahealth-promoting agent2 Evidence-Based Complementary and Alternative Medicine
has been limited [21]. To improve the solubility and bio-
availability of propolis, an encapsulation techniane has
been used [22]. In this study, we explored the eﬀects of
encapsulated propolis on the metabolic and insulin-resist-
ance state of type 2 diabetic rats. The aims were to, (i) verify
thepositiveeﬀectsofencapsulatedpropolisonmodulateglu-
cose and lipid metabolism in T2DM rats, (ii) investigate its
eﬀects on insulin resistance, and (iii) investigate the optimal
concentrations and intake period for T2DM treatment.
2.Materialsand Methods
2.1. Laboratory Animals. Male Sprague-Dawley rats of about
270∼370g were provided by the Shanghai Laboratory Ani-
mal Center of the Chinese Academy of Sciences (Certiﬁcate
of animal quality: Zhong Ke Dong Guan No. 003). All
animals were housed in a rat breeding room with air condi-
tioning and an air defecation ﬁltering device. The rats were
allowed a standard pellet diet, free access to tip ﬁlter water
and maintained at 23 ± 2◦C, 50–70% humidity, a noise
level <50dB, and with 12h dark/12h light cycles. All the
conditions were keeping with the Helsinki accord and the
experimental protocol was approved by the Animal Ethics
Committee of Zhejiang University.
2.2. Drugs and Reagents. Propolis was obtained from
colonies of honeybees, A. mellifera L.,i nn o r t hC h i n ai n
2009, and the main plant origin was poplar (Populus sp.).
Encapsulatedpropoliswaspreparedaccordingtoa published
technical [22] with minor modiﬁcations: raw propolis was
pulverized in a mill then extracted with 80% ethanol to
prepare a 1% ethanol extracts of propolis(EEP), 1% EEP
was stirred into 5% beta-cyclodextrin aqueous solution,
a n dt h em i x e dl i q u o rw a ss o n i c a t e df o r1 5 m i na t2 5 k H z ;
after being sonicated, the sample was rotary evaporated to
remove the ethanol, and spray-drying technique was used
to obtain the encapsulated propolis. Encapsulated propolis
used in this study possesses a grain size about 210nm
with 98.82% encapsulation rate and 29.65% drug-loading
rate of EEP and showed a strong dissolubility in water.
T h et o t a lﬂ a v o n o i d sw e r eu s e da st h em a r k e rf o rq u a l i t y
control of encapsulated propolis, and the content of it was
93.20mg/g [23]. Streptozotocin (STZ) was obtained from
Alexis Corporation; pioglitazone HCL tablet was obtained
fromHangzhouHuadongMedicineGroupCo.,Ltd.;heparin
Sodium Injection and Insulin Injection were obtained from
Nanjing Xinbai Pharmaceutical Co., Ltd.; blood glucose test
kit,TC test kit,TG test kit, and HDL-Ctest kitwere obtained
from Shanghai Shenergy Biotechnology Co., Ltd.; LDL-C
test kit was obtained from Shanghai Fosun Long March
Medical Science Co., Ltd.; insulin radio-immunity test kit
wasobtainedfromBeijingKemeiDongyabiotechnologyCo.,
Ltd.
2.3. Induction of Type 2 Diabetic Mellitus (T2DM) Rat
Model. During experimental session, male Sprague-Dawley
rats (n = 100) were fed with a high-fat diet (HFD)
consisting (as a percentage of total kcal) of 41% fat, 41%
carbohydrate, and 18% protein. And injected with low-dose
S T Z4t i m e sev e ry6d a y st oi n d u c et h ea n i m a le m e r g eT 2 D M
symptom [24]. Brieﬂy, all animals were fasted over night and
then injected with STZ into the tail vein via a temporary
indwelling 24-gauge catheter. The doses of STZ for each
injection were 10mg/kg, 5mg/kg, 20mg/kg, and 10mg/kg,
respectively. Animals had free access to food and water
during each interval of STZ injection. After a week of the
last STZ injection, a casual blood glucose, 12h-fast glucose,
water intake, and urine output were measured. The animals
showingacasualbloodglucoselevels>11.1mmol/Landwith
the symptom of polyuria and polydipsia were considered
diabetic (n = 68, and 60 within them were selected for next
studies).
2.4. Grouping and Drug Administration. T2DM rats were
randomly divided into 5 groups via fasting glucose and
fasting body weight (n = 1 2 ) :m o d e lc o n t r o lg r o u p ,l o w -
, middle- and high-dose encapsulated propolis group, and
positive control group. These 5 groups were continued on
their HFD for the duration of the study. Select another 12
normal male SD rats as normal control group and fed with a
normal chow diet (consisting of 12% fat, 60% carbohydrate,
and 28% protein). Low, middle and high dose encapsu-
lated propolis group were administrated with encapsulated
propolis 50, 100, 200mg/kg·d, positive control group were
administrated with an insulin sensitizer, pioglitazone HCL
tablet, 10mg/kg.d, normal and model control group were
administrated with ﬁltered water at the rate of 1mL/100g.d.
The administration continued for 10 weeks.
2.5. Biological Assays. The animal’s fasting body weight was
observed once a week. Every 2 weeks, blood was collected
from rats’ vena orbitalis posterior, and the serum was
centrifuged at 3000rpm to test FBG and TG. At the end of
the study, FINS were measured and insulin action index
(IAI = 1/FBG×FINS) were calculated [25], the values were
transformed by taking the natural logarithm (Ln), TC, and
HDL-C and LDL-C, were also determined.
2.6. Euglycemic Hyperinsulinemic Glucose Clamp Technique.
Euglycemic hyperinsulinemic glucose clamp technique is a
highly sophisticated labor-intensive method for the determi-
nation of in vivo insulin sensitivity; we performed glucose
clamp studies in subgroups of rats. 12 T2DM rats (6
treated with EP and 6 as model control) and 6 normal rats
were surgically prepared for the clamp procedure and then
gavaged with encapsulated propolis 100mg/kg·do rw i t h
ﬁltered water 1mL/100g·d. for 6 days. All animals under-
went a fasting period of 12h and were anaesthetized with an
intraperitoneal injection of sodium pentobarbital 65mg/kg.
All rats were placed on their back, then the left common
carotid artery and the left jugular vein was exposed, a pol-
yethylene tube were cannulated for collecting blood samples
and administration of insulin and glucose. The technique
used for the glucose clamp was the same as that described
previously [26]. Brieﬂy, each unconscious rat was placed
in a foam plastic jacket that allowed movement of all fourEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀect of encapsulated propolis treatment on body
w e i g h ti nT 2 D MR a t s .V a l u e sa r ee x p r e s s e da st h em e a n s( s t a n d a r d
deviations not shown).
limbs and forward vision during the euglycemic clamp.
Insulin infusion was commenced using an infusion pump
(50mU/kgattherate of0.1mL/min) soastomaintain blood
glucose at the basal level. After 1min of insulin infusion,
the ﬁrst test glucose sample was determined and glucose
infusion was commenced at the rate of 5mg/kg/min. The
infusion lasted for 120min. Ten microliters of arterial blood
glucose was sampled at 5min intervals for determination of
the blood glucose level. The average rate of glucose infusion
(GIR) for the last 35min was taken as the index of insulin
sensitivity (M value) of each rat.
2.7. Data Analysis. Data were reported as means ± standard
deviations. Prior to analysis, Levene’s test and the Kol-
mogorov Smirnov test were used to test for homogeneity of
thevariancesandnormalityoftheresponsevariables,respec-
tively. All the response variables passed tests of normality
(Kolmogorov Smirnov test: P>. 10). Since homogeneity
of the variances was not meet for all the variables (Levene
test: P<. 01), we used the ln transformation to stabilize the
variances. The ln transformed response variables were used
in the statistical analyses. Comparisons between groups over
six time periods were made using time repeated measures
ANOVA with the six time periods as the within-subjects
factor and groups as the between-subjects factor. Signiﬁ-
cant eﬀects were further examined using Tukey’s multiple
pairwise comparisons tests with a probability level of P<
.05 being considered as signiﬁcant. MANOVA procedures
using Wilk’s lambda were used to test for overall diﬀerences
in response variables between the time periods and for
interaction eﬀects between time periods and groups.
3.Results
3.1. Animal Characteristics. Figure 1 shows the body weight
of normal rats and T2DM rats treated with or without
encapsulated propolisor positive drug. The results show that
there were no diﬀerences in body weight at the beginning
of drug administration (P>. 05), at the following 10 weeks
periodofdrugadministration, thebodyweightofeachgroup
increased gradually. Three weeks after drug administration,
the body weight of model control group increased signiﬁ-
cantly than normal control group contemporary (P<. 05,
P<. 01), and body weight of encapsulated propolis treated
groups increased at equal pace with model control group
(P>. 0 5 ) ;h o w e v e r ,t h eb o d yw e i g h to fT 2 D Mr a t st r e a t e d
with positive drug increased quicker than model control
group, and had signiﬁcant diﬀerence on 7th and 10th week
of drug administration (P<. 05).
3.2. FBG in T2DM Rats Treated with Encapsulated Propolis.
The means and standard deviations of encapsulated propolis
over six time periods on FBG in T2DM rats are given in
Table 1. The results of the time repeated measures ANOVA
and MANOVAshow signiﬁcant groupeﬀectonfasting blood
glucose (F = 39.4, df = 5,66, P<. 0001), signiﬁcant
time eﬀect on fasting blood glucose (F = 8.8, df = 5,330,
P<. 0001) and signiﬁcant interaction eﬀect on fasting blood
glucose (F = 3.9, df = 25,330, P<. 0001). The MANOVA
results also show signiﬁcant time period eﬀect on fasting
blood glucose (Wilks λ = 0.630, F = 7.28, df = 5,62,
P<. 0001) and signiﬁcant interaction eﬀect between time
periods and groups on fasting blood glucose (Wilks λ =
0.332, F = 3.20, df = 25,231.8, P<. 0001).
Tukey’s multiple pairwise comparisons test results show
that after the induction of T2DM, FBG concentration in
T2DM model control group was signiﬁcantly higher than
normal control group (P<. 01), and at the following 10-
week period of drug administration, the FBG in model
control group increased with time (P<. 01); however, there
were no signiﬁcant increases of FBG in T2DM rats treated
with encapsulated propolis or positive drug (P>. 05). No
signiﬁcant diﬀerences were found on FBG between model
control group and drug-treated groups at the end of the ﬁrst
4 weeks of drug administration (P>. 05),while after 6 weeks
of drug administration, the FBG concentration in middle-
and low-dose encapsulated propolis groups and positive
controlgroup issigniﬁcantly lower thanmodelcontrolgroup
(P<. 01), and after 8 weeks, the FBG concentration in
high- middle- and low-dose encapsulated propolis groups
and positive control group is signiﬁcantly decreased than
model control group (P<. 01).
3.3. FINS and IAI in T2DM Rats Treated with Encapsulated
Propolis. The eﬀects of encapsulated propolis on FINS and
I A Ii nT 2 D MR a t sa r eg i v e ni nTable 2. The results show
that the level of FINS in T2DM model control group
were signiﬁcantly higher than normal control group (P<
.01), while in middle-dose encapsulated propolis group and
positive control group, the FINS level were decreased sig-
niﬁcantly than model control group (P<. 01). The IAI in
model control group were signiﬁcantly lower than normal
control group (P<. 01), treated with encapsulated propolis
or positive drug can improve the IAI in T2DM rats, the IAI
inhigh-, middle- andlow-doseencapsulatedpropolisgroups
and positive control group were signiﬁcantly higher than
model control group (P<. 01).4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀects of encapsulated propolis on FBG in T2DM rats (x ± S.D.).
Group Dosage n Fasting blood glucose (mmol/L)
(administration) 0 week 2 week 4 week 6 week 8 week 10 week
Normal control 1mL/100g
distilled water (p.o.)
12 6.07 ±0.31∗∗ 6.18 ±0.21∗∗ 6.09 ± 0.28∗∗ 6.09 ±0.24∗∗ 6.13 ±0.24∗∗ 6.19 ±0.33∗∗
Model control 1mL/100g
distilled water (p.o.)
12 7.35 ±0.69 7.39 ± 0.46 7.51 ±0.76 8.23 ±0.84 8.61 ±0.73 9.05 ±1.06
Low-dose EP 50mg/kg encapsulated
propolis (p.o.)
12 7.30 ±0.77 7.82 ± 0.52 7.67 ±0.69 7.13 ±0.52∗∗ 7.74 ±0.49∗∗ 7.88 ±0.46∗∗
Middle-dose EP 100mg/kg encapsulated
propolis (p.o.)
12 7.20 ±1.73 7.79 ± 0.70 7.68 ±0.64 7.51 ±0.50∗∗ 7.59 ±0.40∗∗ 7.51 ±0.50∗∗
High-dose EP 200mg/kg encapsulated
propolis (p.o.)
12 7.17 ±1.20 7.68 ± 0.84 7.63 ±0.85 7.67 ±0.41 7.32 ±0.60∗∗ 7.37 ±0.68∗∗
Positive control 10mg/kg
Pioglitazone HCL (p.o.)
12 7.28 ±1.45 7.68 ± 0.72 6.93 ±0.64 7.01 ±0.47∗∗ 7.53 ±0.45∗∗ 7.54 ±0.46∗∗
Tukey post-hoc tests: ∗P<. 05 and ∗∗P<. 01 compared with model control group.
Table 2: Eﬀects of encapsulated propolis on FINS and IAI in T2DM Rats (x ± S.D.).
Group Dosage (administration) n Fasting serum insulin (μIU/mL) Insulin action index
Normal control 1mL/100g
distilled water (p.o.)
12 39.75 ±10.85∗∗ −5.44 ±0.30∗∗
Model control 1mL/100g
distilled water (p.o.)
12 55.85 ±7.87 −6.17 ±0.22
Low-dose EP 50mg/kg
encapsulated propolis (p.o.)
12 43.65 ±8.32 −5.79 ±0.27∗∗
Middle dose EP 100mg/kg
encapsulated propolis (p.o.)
12 40.80 ±10.99∗∗ −5.60 ±0.55∗∗
High-dose EP 200mg/kg
encapsulated propolis (p.o.)
12 44.21 ±5.50 −5.76 ±0.14∗∗
Positive control 10mg/kg
Pioglitazone HCL (p.o.)
12 40.55 ±14.88∗∗ −5.64 ±0.20∗∗
The data were measured at the end of study. ∗P<. 05 and ∗∗P<. 01 compared with model control group.
3.4. TG in T2DM Rats Treated with Encapsulated Propolis.
The means and standard deviations of encapsulated propolis
on serum TG in T2DM rats are given in Table 3.T h er e s u l t s
of the time repeated measures ANOVA and MANOVA show
signiﬁcant group eﬀect on TG (F = 12.4, df = 5,66, P<
.0001), signiﬁcant time eﬀect on TG (F = 25.7, df = 5,330,
P<. 0001) and signiﬁcant interaction eﬀect on TG (F = 6.5,
df = 25,330, P<. 0001). The MANOVA results also show
signiﬁcant time eﬀect on TG (Wilks λ = 0.409, F = 17.9,
df = 5,62, P<. 0001) and signiﬁcant interaction eﬀect
between weeks and group on TG (Wilks λ = 0.191, F = 5.2,
df = 25,231.8, P<. 0001).
Tukey’s multiple pairwise comparisons test results show
that in the remaining 10 weeks of drug administration, the
TG concentration in model control group were increased
with time (P<. 01), 4 weeks after drug administration, the
TGlevelinmodelcontrolgroupwassigniﬁcantlyhigherthan
normal control group(P<. 01). Encapsulated propolis or
positive drug can depress the TG level in T2DM rats; at 4th
or 6th week of drug administration, TG level in middle-,
low-dose encapsulated propolis groups and positive control
group was signiﬁcantly lower than model control group (P<
.01, P<. 05), and after 8 weeks of drug administration,
the TG level in all encapsulated propolis treated groups
and positive control group were signiﬁcantly decreased than
model control group (P<. 01).
3.5. TC, HDL-C, and LDL-C in T2DM Rats Treated with
Encapsulated Propolis. The eﬀects of encapsulated propolis
on TC, HDL-C, and LDL-C in T2DM rats are given in
Table 4. The results show that there were no signiﬁcant
diﬀerence in TC and HDL-C between model control group
andnormalcontrolgroup(P>. 05),whiletheLDL-Clevelin
model control group were signiﬁcantly higher than normal
control group (P<. 01). There were no signiﬁcant diﬀerence
on TC, HDL-C, and LDL-C level between encapsulated
propolis-treated groups and T2DM model groups (P>
.05), and the LDL-C level in positive control group was
signiﬁcantly lower than model control group (P<. 05).
3.6. Glucose Clamp Study. As shown in Figure 2,t h ea v e r a g e
rate of glucose infusion during the last 35min of glucose
clamp, as an index of insulin sensitivity (M value), was
signiﬁcantly lower in the T2DM model control group thanEvidence-Based Complementary and Alternative Medicine 5
Table 3: Eﬀects of encapsulated propolis on TG in T2DM rats (x ± S.D.).
Group Dosage n Serum triglycerides (mmol/L)
(administration) 0 week 2 week 4 week 6 week 8 week 10 week
Normal control 1mL/100g
distilled water (p.o.)
12 1.67 ±0.40 1.89 ±0.34 1.78 ±0.38∗∗ 1.80 ±0.27∗∗ 1.82 ±0.39∗∗ 2.17 ±0.37∗∗
Model control 1mLl/100g
distilled water (p.o.)
12 1.56 ±0.34 1.59 ±0.34 2.89 ±0.70 2.98 ±0.58 3.09 ±0.54 3.08 ±0.74
Low-dose EP
50mg/kg
encapsulated propolis
(p.o.)
12 1.60 ±0.42 1.77 ±0.55 2.27 ±0.53∗ 2.10 ±0.38∗∗ 2.15 ±0.60∗∗ 2.32 ±0.59
Middle-dose EP
100mg/kg
encapsulated propolis
(p.o.)
12 1.65 ±0.37 1.79 ±0.51 2.00 ±0.26∗∗ 1.78 ±0.46∗∗ 1.50 ±0.45∗∗ 1.54 ±0.59∗∗
High-dose EP
200mg/kg
encapsulated propolis
(p.o.)
12 1.68 ±0.44 1.84 ±0.52 2.43 ±0.49 2.48 ±0.47 2.18 ±0.58∗∗ 2.13 ±0.65∗∗
Positive control 10mg/kg
PioglitazoneHCL (p.o.)
12 1.75 ±0.55 1.60 ±0.36 2.13 ±0.47∗∗ 1.87 ±0.76∗∗ 1.98 ±0.69∗∗ 1.59 ±0.46∗∗
Tukey post hoc tests: ∗P<. 05 and ∗∗P<. 01 compared with model control group.
Table 4: Eﬀects of encapsulated propolis on TC, HDL-C, LDL-C in T2DM Rats (x ± S.D.).
Group Dosage (administration) n Total cholesterol HDL cholesterol (mmol/L) LDL cholesterol
Normal control 1mL/100g distilled water
(p.o.)
12 2.10 ±0.47 1.02 ±0.19 0.21 ±0.08∗∗
Model control 1mL/100g
distilled water (p.o.)
12 2.24 ±0.28 1.09 ±0.26 0.32 ±0.07
Low-dose EP 50mg/kg
encapsulated propolis (p.o.)
12 2.22 ±0.44 1.14 ±0.21 0.27 ±0.05
Middle-dose EP 100mg/kg
encapsulated propolis (p.o.)
12 2.34 ±0.48 1.12 ±0.19 0.29 ±0.06
High-dose EP 200mg/kg
encapsulated propolis (p.o.)
12 2.15 ±0.35 1.11 ±0.17 0.26 ±0.05
Positive control 10mg/kg
Pioglitazone HCL (p.o.)
12 2.00 ±0.50 0.90 ±0.18 0.24 ±0.02∗
The data were measured at the end of study. ∗P<. 05 and ∗∗P<. 01 compared with model control group.
normal control group (P<. 01). Encapsulated propolis
(100mg/kg.d) signiﬁcantly improved the M value compared
to that in model control group (P<. 01).
4.Discussion
Insulin resistance and insulin secrete defection are two
important factors in the pathogenesis of T2DM. The results
of this study showed thatthe concentrationof FBG and FINS
in T2DM model rats was signiﬁcantly higher than normal
rats (P<. 01), while IAI and the rate of glucose infusion
in glucose clamp experiment were signiﬁcantly lower than
normal rats (P<. 01), indicating the hyperglycemia
of this T2DM model we induced was mainly caused by
insulin resistance not by insulin secrete defection; the results
conﬁrmed those of previous studies that showed feeding
healthy rats with a high-fat diet and injected with low-dose
STZ results in insulin resistance and hyperglycemia [27].
Unlike type 1 diabetes mellitus, being emaciated is not
the feature of T2DM, many T2DM as individuals often
suﬀered obesity. The results showed that the T2DM model
rats became middle obesity with the course of T2DM disease
prolonging, and the body weight of T2DM model control
group were signiﬁcantly higher than normal control group
after 3 weeks handling (P<. 05); the positive drug piogli-
tazone HCL tablet increased the body weight of T2DM rats
(P<. 05), which departure the antiobesity treatment policy
of T2DM [28]. Otherwise, the results show no signiﬁcant
eﬀect on body weight of T2DM rats treated with encapsu-
lated propolis.
Hyperglycemia is a macroscopic manifestation of T2DM
symptom, and persistence hyperglycemia will aﬀect cells,
tissues, andorgans all overthebody,as itis themain factor to
cause diabetes chronic complications. The correlation be-
tween risk ofmicrovascularcomplicationsand bloodglucose
control was elucidated by the diabetes control and complica-
tions trial (DCCT) and the UK prospective diabetes study
(UKPDS), which have provided evidence to link glycemic6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Insulin sensitivity in the normal control and T2DM rats
treated with or without encapsulated propolis (100mg/kg·d) for 6
days. Values are expressed as the means ± standard deviations.
control and the reduction of risk of diabetic complications
[29]. To achieving and maintaining near-normoglycemia is
imperative to prevent or delay the onset and progression of
long-term complications of the disease. The data obtained
from the study showed that encapsulated propolis can
depress the heightening of FBG in T2DM rats; 8 weeks after
drug administration, the FBG in T2DM rats treated with
encapsulated propolis was signiﬁcantly depressed than
T2DM model rats (P<. 01), indicate encapsulated propolis
was eﬃciency for T2DM blood glucose controlling.
Typically, insulin resistance is an early feature of the
T2DM condition, which is initially compensated in part by
increased production of insulin by pancreatic β-cells (hy-
perinsulinaemia). Subsequently, as these β-cells become
“exhausted”, the combined eﬀects of insulin resistance and
impaired insulin secretion reduce insulin-mediated glucose
uptakeandutilizationbyskeletalmuscleandpreventinsulin-
mediated suppression of hepatic glucose output. Contin-
uing deterioration of endocrine control exacerbates these
metabolic disturbances and increases the hyperglycemia
[30]. Thus, to improve the insulin sensitivity becomes a very
important treatment target in T2DM [31]. In this study, IAI
was measured to evaluate the eﬀect of encapsulated propolis
on insulin resistance in T2DM rats, and euglycemic hyper-
insulinemic clamp, the method considered as “the gold stan-
dard” in measuring insulin resistance, was be used to assess
accurately the rate of whole-body glucose disposal during
steady-state hyperinsulinemia [32]. The results showed the
IAI and the average rate of glucose infusion in euglycemic
hyperinsulinemic clamp experiment (GIR or M value) were
improved signiﬁcantly than T2DM model rats (P<. 01),
conﬁrming that encapsulated propolis can improve the
insulin sensitivity in T2DM rats.
Lipoidosis is a primarily pathological change in T2DM
and its long-term complications, as some experts prefered
that there might be more rewarding to approach T2DM
as “lipocentric” than “glucocentric” [33]. It has long been
known that in addition to hyperglycemia, the type 2 diabetic
individual almost invariably manifests a serious breakdown
in lipid dynamics, often reﬂected by elevated levels of TG,
together with excessive deposition of fat in various tissues
including the muscle bed [34, 35]. The depressed activity
of insulin-mediated lipoprotein lipase (LPL) made the clear-
ance rate of lipoprotein descend, which is the main cause
of hypertriglyceridemia in T2DM disease [36]. The results
show that encapsulated propolis can inhabit the increasing
of TG levels in T2DM rats, and it is possibly proﬁted by the
amendment of insulin sensitivity and LPL activity in treated
with encapsulated propolis. The results show no signiﬁcant
diﬀerence on TC, LDL-C, and HDL-C between encapsulated
propolis treated rats and model rats (P>. 05).
It is recommended that appropriate diets, regular exer-
cise, and weight control have potential for the prevention
of type 2 diabetes, and ideally, a combination of improved
diet, exercise, supplementation, and insulin-sensitizing pre-
scription drugs can reverse mild hyperglycemia to moderate
one before stronger drugs are needed. Our data indicated
that encapsulated propolis can inhibit the increase of fasting
serumglucose,modulatelipidmetabolismaswell asimprove
the insulin sensitivity in T2DM rat and, therefore, to delay
the development of diabetes. Since this animal model we
induced is similar to that of the early-to-moderate stage of
T2DM in human beings, the ﬁndings provide some evi-
dences of the use of encapsulated propolis in the prevention
or in the treatment in the early stages of type 2 diabetes.
However, to transfer the results of this animal model to
humans requires further investigations.
5.Conclusion
Our data indicated that encapsulated propolis exert multiple
beneﬁcial eﬀectsin fat-fed, streptozotocin-treated type2dia-
betes.Improvementofhyperglycemiaandhyperlipidaemiais
associatedwithamarkedincreaseofinsulinsensitivity.These
ﬁndings further support the use of encapsulated propolis in
thetreatmentoftype2diabetesandemphasizethepossibility
that the deterioration of blood glucose concentration over
time may be prevented.
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